Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
adding to our strongpipeline in this therapeutic area. ...About glucagon receptor (GCGR) target of ISIS 325568 ...Glucagon is a hormone that opposes the action of insulin and stimulate...About glucocorticoid receptor (GCCR) target of ISIS 377131 ...Glucocorticoid hormones have a variety of effects throughout the body...
Date:9/13/2007
adding to our strong
pipeline in this therapeutic area."
About glucagon receptor (GCGR), target of ISIS 325568
Glucagon is a hormone that opposes the action of insulin and stimulates
the liver to produce glucose. In Type 2 diabetes, unopposed action of
glucagon can lead to increased blood glucose levels. Reducing the
expression of liver GCGR using antisense inhibitors, and thereby reducing
excessive liver glucose production, is expected to lower blood glucose
levels and help control Type 2 diabetes. In preclinical studies, antisense
inhibitors of GCGR led to improved glucose control and reduced levels of
blood triglycerides without producing hypoglycemia. In addition, treatment
with ISIS 325568 led to an increase in circulating glucagon-like peptide,
or GLP-1, which is a hormone that helps to preserve pancreatic function,
thereby enhancing insulin secretion.
About glucocorticoid receptor (GCCR), target of ISIS 377131
Glucocorticoid hormones have a variety of effects throughout the body,
including promoting liver glucose production and fat storage. Although
inhibition of GCCR has long been recognized as an attractive strategy for
development of therapeutics for Type 2 diabetes, the side effects
associated with systemic GCCR inhibition have challenged development of
traditional drugs. Antisense inhibitors of GCCR take advantage of the
unique tissue distribution of oligonucleotides that allows the antisense
drugs to antagonize glucocortocoid action primarily in liver and fat
tissue. Notably, antisense drugs do not reduce GCCR expression in the
central nervous system or adrenal glands -- inhibition of GCCR expression
in these two organs can lead to systemic side effects. In preclinical
studies, Isis has shown that ISIS 377131 has a broad therapeutic profile
that includes reduction of blood glucose levels, a dramatic and favorable
effect on lipid levels including cholesterol and triglycerides, and a
reduction in body fat.
Conference Call'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
WARF enters licensing agreements for stem cell products2.
Virent enters agreement with Shell Oil unit to make hydrogen with biomass3.
Software company enters health space with RFID solutions on hold4.
Lucigen Corp. enters global licensing agreement5.
Call centers and customer service: The good, the bad, and the clueless6.
GE Healthcare enters agreement with Canadian health authority7.
Data centers: Buyers beware of over-hyped facilities8.
Data centers: Blowing smoke and raising red flags9.
Prodesse enters patent agreement with Roche10.
UW-Madison enters Kauffman grant competition11.
Applied Technology Centers to aid printing and manufacturing
(Date:12/10/2009)... Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... sciences product development company that identifies and advances ... various stages of development, today provided an update ... the merger of Cytopia Ltd. into YM, details ... The board of directors of Cytopia has unanimously ...
(Date:12/10/2009)... -- China Biologic,Products, Inc. (Nasdaq: CBPO ) ... plasma-based biopharmaceutical companies in China, today announced,that the ... bell at the,NASDAQ MarketSite in New York City ... , China Biologic,s common ... on,December 2, 2009, under the ticker symbol "CBPO." ...
(Date:12/10/2009)... -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: LTUS) ... and,producer of prescription drugs and licensed national ... of China ("PRC"), today reported that,effective December ... entity of Lotus,appointed Mr. Jinzhong HAN to ... division ("OTC Division"). , ...
(Date:12/10/2009)... that it has entered into a multi-year, sole-source supply agreement ... the use of Martek’s products in Fonterra’s infant formulas and ... , ... Columbia, MD (Vocus) December 10, ... today that it has entered into a multi-year, sole-source supply ...
Breaking Biology Technology:YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4China Biologic Products to Ring NASDAQ Opening Bell 2China Biologic Products to Ring NASDAQ Opening Bell 3Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3... fund to provide capital for local and regional innovations received ... Economic Development Corporations Board of Directors. , ,Developed as ... competition, the Family and Friends Innovation Development Fund will be ... A maximum of $7,500 per project for up to three ...
... in downtown Madison and you could try out the city's ... on Wednesday. , ,An initial coverage area of 10 ... is operational and available for testing. And until April 1, ... Internet service providers will be selling service for monthly rates. ...
... subsidiary of Milwaukee-based Merge Healthcare, said it will ... surgeons . , ,The company's OrthoWorks product will ... communications system (PACS), helping support joint arthroplasty, spine, ... the firm said. , ,Mayo Clinic has 70 ...
Other Biology Technology:Wireless advances in Madison, heats up in Waukesha 2Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products:Biology NavigationMedical Navigation 